PsiOxus Therapeutics Ltd
Trending Articles
Related Content
Regulatory
CTA for armed oncolytic virus treatment of solid tumours
PsiOxus Therapeutics, announced the clinical trial application (CTA) for NG-348, an ‘armed’ oncolytic virus for the treatment of solid tumours, has been approved and per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus